0000000000790354

AUTHOR

A. La Neve

showing 3 related works from this author

Insight into epileptic and physiological déjà vu: from a multicentric cohort study

2019

Background and purpose The presence of a continuum between physiological deja vu (DV) and epileptic DV is still not known as well as epidemiological data in the Italian population. The aim was to identify the epidemiological distribution of DV in Italy, and secondly to look for specific features of DV able to discriminate between epileptic and non-epileptic DV. Methods In all, 1000 individuals, 543 healthy controls (C) (313 women; age 40 ± 15 years) and 457 patients with epilepsy (E) (260 women; age 39 ± 14 years), were prospectively recruited from 10 outpatient neurological clinics throughout Italy. All populations were screened using the Italian Inventory for Deja Vu Experiences Assessmen…

AdultMalemedicine.medical_specialtymedia_common.quotation_subjectNeurocognitive Disordersepilepsy; epileptic déjà vu; physiological déjà vu; Adult; Cohort Studies; Epilepsy; Female; Humans; Italy; Male; Middle Aged; Neurocognitive Disorders; Recognition Psychology; Deja VuCohort Studies03 medical and health sciencesEpilepsy0302 clinical medicineEpidemiologyHumansPsychologyMedicine030212 general & internal medicinePsychiatrymedia_commonbusiness.industryphysiological déjà vuRecognition PsychologyMiddle AgedDeja Vumedicine.diseaseItalian populationepileptic déjà vuRecognitionItalyNeurologyFeelingDéjà vuEtiologyepilepsyFemaleNeurology (clinical)Epileptic seizuremedicine.symptombusiness030217 neurology & neurosurgeryCohort study
researchProduct

Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, RealWorld Study

2022

Introduction: In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Most real-world research on BRV has focused on refractory epilepsy. The aim of this analysis was to assess the 12-month effectiveness and tolerability of adjunctive BRV when used as early or late adjunctive treatment in patients included in the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST). Methods: BRIVAFIRST was a 12-month retrospective, multicenter study including adult patients prescribed adjunctive BRV. Effectiveness outcomes included the rates of sustained seizure response, sustained seizure freedom, and treatment discontinua…

Antiseizure medicationFocal seizuresAntiseizure medication; Brivaracetam; Epilepsy; Focal seizures.Antiseizure medication; Brivaracetam; Epilepsy; Focal seizures;EpilepsyNeurologyBrivaracetamSettore MED/26 - NeurologiaNeurology (clinical)Antiseizure medication; Brivaracetam; Epilepsy; Focal seizuresSettore MED/26Settore MED/39 - Neuropsichiatria Infantile
researchProduct

Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)

2021

Background: In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Studies performed in a naturalistic setting are a useful complement to characterize the drug profile. Objective: This multicentre study assessed the effectiveness and tolerability of adjunctive BRV in a large population of patients with focal epilepsy in the context of real-world clinical practice. Methods: The BRIVAFIRST (BRIVAracetam add-on First Italian netwoRk STudy) was a retrospective, multicentre study including adult patients prescribed adjunctive BRV. Patients with focal epilepsy and 12-month follow-up were considered. Main outcomes includ…

medicine.medical_specialtybusiness.industryContext (language use)Brivaracetammedicine.diseaseDiscontinuationlaw.inventionPsychiatry and Mental healthEpilepsyRandomized controlled trialTolerabilityfocal epilepsy add-on therapy seizurelawConcomitantInternal medicineMedicinePharmacology (medical)Neurology (clinical)LevetiracetamOriginal Research Articlebusinessmedicine.drug
researchProduct